Rani Therapeutics Holdings
Filed with the SEC on · accession 0001193125-26-453872
RANI filed a 10-Q (quarterly report) with the SEC on Nov 9, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved +5.0% by the first close after the filing.
Rani Therapeutics Holdings filed its quarterly 10-Q report for the period ending September 30, 2026, disclosing financial results and ongoing collaboration agreements with Chugai Pharmaceutical and ProGen.
Close before
$0.55
Nov 6, 2026
First close after
+5.03%
$0.57
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for RANI, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for RANI?
Click hereRANI filed a 10-Q (SEC filing). Rani Therapeutics Holdings filed its quarterly 10-Q report for the period ending September 30, 2026, disclosing financial results and ongoing collaboration agreements with Chugai Pharmaceutical and ProGen.
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
RANI closed at $0.55 before the filing and $0.57 on Nov 9, 2026 (+5.03%).
Get alerts when RANI files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days